Drug intelligence / Profile preview

PB002

Development stage: Preclinical
Lead developer: PharmaBiome
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

PB002 is a rationally designed, co-cultured bacterial consortium being developed by PharmaBiome for the treatment of ulcerative colitis. As a live biotherapeutic product, it consists of nine specific bacterial strains selected to restore missing functional niches in the dysbiotic gut microbiome of patients. Unlike traditional fecal microbiome transplantation (FMT), PB002 is produced using a proprietary co-culture technology in bioreactors, ensuring a defined, standardized, and scalable composition. The therapy is designed for oral administration and aims to restore intestinal homeostasis and address the underlying functional deficiencies that drive chronic inflammation in inflammatory bowel disease, rather than merely managing symptoms.

Other names: bacterial consortium (UC)PharmaBiome UC therapy

Beyond the preview

Go deeper on PB002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB002.

Explore the full profile